Ozurdex may be effective for BRVO prognosis

Article

Ozurdex could have a beneficial effect on the visual prognosis in branch retinal vein occlusion (BRVO), reveals a study in Eye.

Ozurdex could have a beneficial effect on the visual prognosis in branch retinal vein occlusion (BRVO), reveals a study in Eye.

A team led by Dr E. Moisseiev, Department of Ophthalmology, Tel Aviv Medical Centre, Affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, assessed a total of 17 patients who were administered Ozurdex injections as part of the GENEVA study.

The outcome measures included final visual acuity (VA), final retinal thickness by optical coherence tomography, persistence of macular oedema and the occurrence of complications.

It was found retinal thickness reduced significantly in all patients, but 12 patients experienced cataract progression, one had neovascularization and one had vitreous haemorrhage.

BRVO patients demonstrated a more favourable prognosis than CRVO patients. The mean VA of the BRVO patients improved significantly, whereas this was not true for CRVO patients. Based on the results Ozurdex was deemed to have a favourable long-term safety profile and may provide good outcomes for BRVO patients although further study is requried.

For more information on the study please click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.